{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:12:11Z","timestamp":1790892731062,"version":"4.1.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Psoriasis is a chronic, systemic, inflammatory disease affecting the skin, joints and other organs. Psoriasis negatively affects patients\u2019 quality of life, causing social anxiety and negative coping, thus determining a cumulative life course impairment (CLCI). The concept of CLCI in psoriasis is reinforced by the understanding that psoriasis-associated comorbidities and stigma accumulate over a patient\u2019s life course, resulting from an interaction between the burden of stigmatization, physical and psychological comorbidities, coping strategies and external factors. The concept may help identify more vulnerable patients and facilitate more appropriate treatment decisions or earlier referrals. Although some potential risk factors for CLCI have been clarified, no all-encompassing screening tools are available. Patients at risk for CLCI should be identified by applying clinical, personal and psychosocial indicators and predictors individually.<\/jats:p>\n                  <jats:p>Early intervention in psoriasis treatment could improve long-term patient outcomes and modify the disease course. However, more research is needed to clearly define what constitutes \u2018early\u2019 intervention and to identify the most effective strategies for implementation. From a preventive point of view, it is helpful to identify early interventions aimed at reducing the risk of CLCI and establishing a new life course trajectory in patients with psoriasis. This review summarizes the latest developments in CLCI and psoriasis, highlighting knowledge gaps and future directions to make control of CLCI a possible goal for therapies.<\/jats:p>","DOI":"10.1093\/ced\/llae282","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T18:24:23Z","timestamp":1721672663000},"page":"1525-1531","source":"Crossref","is-referenced-by-count":18,"title":["Early intervention and cumulative life course impairment in psoriasis: a review"],"prefix":"10.1093","volume":"49","author":[{"given":"Luisa Maria Halina","family":"Arancio","sequence":"first","affiliation":[{"name":"Fondazione IRCCS C\u00e0 Granda Ospedale Maggiore Policlinico Milano, ASST Crema , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"D\u2019Amico","sequence":"additional","affiliation":[{"name":"UO di Dermatologia \u2013 P.O. \u2018A. Pugliese\u2019 \u2013 Azienda Ospedaliero Universitaria \u2018Renato Dulbecco\u2019 , Catanzaro ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Dastoli","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliero Universitaria \u2018Mater Domini\u2019 , Catanzaro ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen Silvia","family":"Fiorella","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Mons. Dimiccoli Hospital , Barletta ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Manfredini","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Surgical, Medical, Dental & Morphological Sciences with Interest in Transplant, Oncological & Regenerative Medicine, University of Modena and Reggio Emilia , Modena ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Moretta","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Istituto Dermopatico dell\u2019Immacolata IRCCS Roma , Roma ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Paolino","sequence":"additional","affiliation":[{"name":"Unit\u00e0 di Dermatologia IRCCS Ospedale San Raffaele Milano, Universit\u00e0 Vita-Salute San Raffaele , Milano ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Levi","sequence":"additional","affiliation":[{"name":"AbbVie Srl, Campoverde di Aprilia , Lazio ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Di Fino","sequence":"additional","affiliation":[{"name":"AbbVie Srl, Campoverde di Aprilia , Lazio ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Zucchi","sequence":"additional","affiliation":[{"name":"AbbVie Srl, Campoverde di Aprilia , Lazio ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Piaserico","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medicine, DIMED, Universit\u00e0 di Padova , Padova ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"key":"2024112216160515700_llae282-B1","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1468-3083.2010.03705.x","article-title":"Psoriasis: is the impairment to a patient\u2019s life cumulative?","volume":"24","author":"Kimball","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024112216160515700_llae282-B2","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1111\/jdv.17348","article-title":"Mapping risk factors for cumulative life course impairment in patients with chronic skin diseases \u2013 a systematic review","volume":"35","author":"von Stulpnagel","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024112216160515700_llae282-B3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.4103\/ijt.ijt_99_20","article-title":"Cumulative life course impairment of alopecia areata","volume":"12","author":"Burns","year":"2020","journal-title":"Int J Trichol"},{"key":"2024112216160515700_llae282-B4","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/rheumatology\/39.6.603","article-title":"How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5\u2005years of follow-up in 732 patients from the Early RA Study (ERAS)","volume":"39","author":"Young","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"2024112216160515700_llae282-B5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/IJGM.S261139","article-title":"Impact of endometriosis on life-course potential: a narrative review","volume":"14","author":"Missmer","year":"2021","journal-title":"Int J Gen Med"},{"key":"2024112216160515700_llae282-B6","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/eos.12206","article-title":"Factors associated with the development of dental caries in children and adolescents in studies employing the life course approach: a systematic review","volume":"123","author":"Abreu","year":"2015","journal-title":"Eur J Oral Sci"},{"key":"2024112216160515700_llae282-B7","author":"World Health Organization"},{"key":"2024112216160515700_llae282-B8","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2024112216160515700_llae282-B9","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000350008","article-title":"Cumulative life course impairment: evidence for psoriasis","volume":"44","author":"Mattei","year":"2013","journal-title":"Curr Probl Dermatol"},{"key":"2024112216160515700_llae282-B10","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ad.2013.02.009","article-title":"Cumulative life course impairment: the imprint of psoriasis on the patient\u2019s life","volume":"105","author":"Ros","year":"2014","journal-title":"Actas Dermosifiliogr"},{"key":"2024112216160515700_llae282-B11","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jaad.2015.06.049","article-title":"Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States","volume":"73","author":"Schaefer","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"2024112216160515700_llae282-B12","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1080\/13696998.2019.1638788","article-title":"Prevalence and economic \u00adburden of comorbid anxiety and depression among patients with moderate-to-severe psoriasis","volume":"22","author":"Cai","year":"2019","journal-title":"J Med Econ"},{"key":"2024112216160515700_llae282-B13","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000350555","article-title":"Cumulative life course impairment: identifying patients at risk","volume":"44","author":"Augustin","year":"2013","journal-title":"Curr Probl Dermatol"},{"key":"2024112216160515700_llae282-B14","doi-asserted-by":"crossref","first-page":"12849","DOI":"10.3390\/ijms232112849","article-title":"Could targeted pharmacotherapies exert a \u2018disease modification effect\u2019 in patients with chronic plaque psoriasis?","volume":"23","author":"Bellinato","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2024112216160515700_llae282-B15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s13555-021-00635-4","article-title":"Evolution of patient perceptions of psoriatic disease: results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) survey","volume":"12","author":"Lebwohl","year":"2022","journal-title":"Dermatol Ther (Heidelb"},{"key":"2024112216160515700_llae282-B16","first-page":"41","article-title":"The impact of genital psoriasis on quality of life: a systematic review","volume-title":"Psoriasis (Auckl)","author":"Yang","year":"2018"},{"key":"2024112216160515700_llae282-B17","doi-asserted-by":"crossref","first-page":"339","DOI":"10.31688\/ABMU.2019.54.2.19","article-title":"Sexual dysfunction in patients with psoriasis","volume":"54","author":"Stanescu","year":"2019","journal-title":"Arch Balkan Med Union"},{"key":"2024112216160515700_llae282-B18","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1111\/jdv.18977","article-title":"Development of measurement tools to assess cumulative life course impairment in patients with chronic skin diseases","volume":"37","author":"Braren-von St\u00fclpnagel","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024112216160515700_llae282-B19","first-page":"102","article-title":"Psoriasis \u2013 the life course approach","volume":"96","author":"Linder","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"2024112216160515700_llae282-B20","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/bjd\/ljac086","article-title":"Exploring disease comorbidities and temporal disease progression of psoriasis: an observational, retrospective, multi-database, cohort study","volume":"188","author":"Roseno","year":"2023","journal-title":"Br J Dermatol"},{"key":"2024112216160515700_llae282-B21","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/bjd.17259","article-title":"Reversibility of alexithymia with effective treatment of moderate-to-severe psoriasis: longitudinal data from EPIDEPSO","volume":"180","author":"Sampogna","year":"2019","journal-title":"Br J Dermatol"},{"key":"2024112216160515700_llae282-B22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/09546634.2018.1476654","article-title":"Comparison of mental health outcomes among adults with psoriasis on biologic versus oral therapies: a population-based study","volume":"30","author":"Salame","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"2024112216160515700_llae282-B23","doi-asserted-by":"crossref","first-page":"e011199","DOI":"10.1161\/CIRCIMAGING.120.011199","article-title":"Treatment of psoriasis with biologic therapy is associated with improvement of coronary artery plaque lipid-rich necrotic core: results from a prospective, observational study","volume":"13","author":"Choi","year":"2020","journal-title":"Circ Cardiovasc Imaging"},{"key":"2024112216160515700_llae282-B24","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2020.08.032","article-title":"Reduced risk of mortality associated with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR): a nested case\u2013control analysis","volume":"84","author":"Langley","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2024112216160515700_llae282-B25","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1111\/jdv.16273","article-title":"The role of the interleukin-23\/Th17 pathway in cardiometabolic comorbidity associated with psoriasis","volume":"34","author":"Egeberg","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024112216160515700_llae282-B26","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.semarthrit.2017.05.010","article-title":"The psychosocial burden of psoriatic arthritis","volume":"47","author":"Husni","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2024112216160515700_llae282-B27","doi-asserted-by":"crossref","first-page":"1027347","DOI":"10.3389\/fmed.2022.1027347","article-title":"Early intervention in psoriasis: where do we go from here?","volume":"9","author":"Felix","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2024112216160515700_llae282-B28","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ad.2022.01.024","article-title":"Practical update of the guidelines published by the psoriasis group of the Spanish Academy of Dermatology and Venereology (GPs) on the treatment of psoriasis with biologic agents: part 2 \u2013 management of special populations, patients with comorbid conditions, and risk","volume":"113","author":"Carrascosa","year":"2022","journal-title":"Actas Dermosifiliogr"},{"key":"2024112216160515700_llae282-B29","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/jdv.16104","article-title":"A Belgian consensus on the definition of a treat-to-target outcome set in psoriasis management","volume":"34","author":"Grine","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024112216160515700_llae282-B30","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/jdv.14114","article-title":"Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis","volume":"31","author":"Gisondi","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024112216160515700_llae282-B31","first-page":"1","article-title":"Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis","volume-title":"Ital J Dermatol Venerol","author":"Gisondi","year":"2022"},{"key":"2024112216160515700_llae282-B32","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/2040622318759282","article-title":"Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment","volume":"9","author":"Chan","year":"2018","journal-title":"Ther Adv Chronic Dis"},{"key":"2024112216160515700_llae282-B33","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2147\/CCID.S296544","article-title":"Risankizumab for the treatment of moderate to severe psoriasis: impact on health-related quality of life and psychological wellbeing","volume":"16","author":"Gracia-Cazana","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae282\/59029847\/llae282.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/12\/1525\/60790387\/llae282.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/12\/1525\/60790387\/llae282.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T11:16:40Z","timestamp":1732274200000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/49\/12\/1525\/7719049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":33,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,7,24]]},"published-print":{"date-parts":[[2024,11,22]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llae282","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,7,24]]}}}